The cardiovascular mortality reduction observed in the 2015 EMPA-REG trial emerged within months of initiating SGLT2 inhibitor treatment
Agree
Disagree
Overview
Debates
Related claims
Topics
Best
Space b5a31f
Loading debates…
Opening sign-in…